Transdermal route is a promising alternative for oral and injectable drug delivery wherein skin is the primary site for drug administration. This drug delivery system offers certain benefits, such as non-invasiveness, controlled & complete drug delivery from the dosage form and improved patient compliance. Transdermal patches, ointments, gel and implants are the popular transdermal drug delivery systems. Over the past few years, transdermal patches have gained significant importance. The transdermal drug delivery market has witnessed vertical growth over the past few decades and this trend is expected to continue during the forecast period. This growth would be driven by the steadily growing number of transdermal drug delivery products in the market resulting from the widespread adoption of these products by consumers. Johnson and Johnson, Acrux, Antares Pharma, Dermatrends Inc., Bayer HealthCare Pharmaceuticals, Novartis, Janssen Pharmaceuticals Inc. and Durect Corporation are some of the key leaders in the global transdermal drug delivery systems market. Recently, NuPathe Inc. received FDA clearance for their transdermal patch, Zeltrix. It is a single use preparation intended for the treatment of migraine pain.
The global transdermal drug delivery systems market is segmented on the basis of application, technology and geography. The application segment is further categorized into CNS, Pain Management, Hormone, Cardiovascular and Others. Transdermal patches for pain management and hormonal drug delivery dominate the market. Vivelle-dot and Climara are estrogen patches currently available in the market, offered by Novartis and Bayer HealthCare Pharmaceuticals, respectively. They are used in the delivery of estradiol for hormone replacement therapy. Based on technology, the global transdermal drug delivery systems market is segmented into Electroporation, Electric current, Lontophoresis, Radio Frequency, Microporation, Thermal, Mechanical arrays and Ultrasound. These technologies form an efficacious drug delivery system by improving the drug distribution pattern across the skin. Geographically, the global transdermal drug delivery systems market is segmented into North America, Europe, Asia-Pacific and LAMEA. North America and Europe dominate the global market due to extensive R&D efforts and presence of numerous approved transdermal products.
KEY BENEFITS
This report offers the following benefits in particular:
KEY MARKET SEGMENTS
The global transdermal drug delivery systems market is segmented into three major categories: application, technology and geography.
MARKET BY APPLICATION
MARKET BY TECHNOLOGY
MARKET BY GEOGRAPHY
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.1. KEY BENEFITS
1.2. KEY MARKET SEGMENTS
1.3. RESEARCH METHODOLOGY
1.3.1. Secondary research
1.3.2. Primary research
1.3.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.2.2.1. Competitive intelligence of companies and their strategies
3.3. MARKET SHARE ANALYSIS, 2016
3.4. MARKET DYNAMICS
3.4.1. Drivers
3.4.1.1. Rising geriatric population
3.4.1.2. Increasing prevalence of chronic disorders
3.4.1.3. Rise in adoption of third-generation delivery systems
3.4.2. Restraints
3.4.2.1. Side-effects of the systems
3.4.3. Opportunities
3.4.3.1. Emerging nations
CHAPTER 4 TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY TYPE OF DELIVERY SYSTEM
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. PASSIVE DELIVERY SYSTEM
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.2.3.1. Matrix delivery system
4.2.3.1.1. Market size and forecast
4.2.3.2. Reservoir delivery system
4.2.3.2.1. Market size and forecast
4.3. ACTIVE DELIVERY SYSTEM
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
4.3.3.1. Structure-based drug delivery system
4.3.3.1.1. Market size and forecast
4.3.3.2. Electrically-based drug delivery system
4.3.3.2.1. Market size and forecast
4.3.3.2.2. Iontophoresis
4.3.3.2.2.1. Market size and forecast
4.3.3.2.3. Electroporation
4.3.3.2.3.1. Market size and forecast
4.3.3.2.4. Sonophoresis
4.3.3.2.4.1. Market size and forecast
4.3.3.3. Other
4.3.3.3.1. Market size and forecast
CHAPTER 5 TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY APPLICATION
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. ANALGESICS
5.2.1. Market size and forecast
5.3. HORMONE REPLACEMENT THERAPY
5.3.1. Market size and forecast
5.4. HYPERTENSION
5.4.1. Market size and forecast
5.5. MOTION SICKNESS
5.5.1. Market size and forecast
5.6. SMOKING CESSATION
5.6.1. Market size and forecast
5.7. OTHERS
5.7.1. Market size and forecast
CHAPTER 6 TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY REGION
6.1. OVERVIEW
6.1.1. Market size and forecast
6.2. NORTH AMERICA
6.2.1. Key market trends
6.2.2. Growth factors and opportunities
6.2.3. Market size and forecast
6.3. EUROPE
6.3.1. Key market trends
6.3.2. Growth factors and opportunities
6.3.3. Market size and forecast
6.4. ASIA-PACIFIC
6.4.1. Key market trends
6.4.2. Growth factors and opportunities
6.4.3. Market size and forecast
6.5. LAMEA
6.5.1. Key market trends
6.5.2. Growth factors and opportunities
6.5.3. Market size and forecast
CHAPTER 7 COMPANY PROFILES
7.1. ACRUX LIMITED
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Business performance
7.1.5. Key strategic moves and developments
7.1.6. Strategy share (%)
7.2. BAYER AG
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Business performance
7.2.5. Key strategic moves and developments
7.2.6. Strategy share (%)
7.3. BOEHRINGER INGELHEIM GMBH
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Business performance
7.3.5. Key strategic moves and developments
7.3.6. Strategy share (%)
7.4. BRISTOL-MYERS SQUIBB COMPANY
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Business performance
7.4.5. Key strategic moves and developments
7.4.6. Strategy share (%)
7.5. ECHO THERAPEUTICS, INC.
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Business performance
7.5.5. Key strategic moves and developments
7.5.6. Strategy share (%)
7.6. ENDO PHARMACEUTICALS INC.
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Business performance
7.6.5. Key strategic moves and developments
7.6.6. Strategy share (%)
7.7. GLAXOSMITHKLINE PLC
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Business performance
7.7.5. Key strategic moves and developments
7.7.6. Strategy share (%)
7.8. JOHNSON & JOHNSON
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Business performance
7.8.5. Key strategic moves and developments
7.8.6. Strategy share (%)
7.9. MYLAN N.V.
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Business performance
7.9.5. Key strategic moves and developments
7.9.6. Strategy share (%)
7.10. NOVARTIS AG
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Business performance
7.10.5. Key strategic moves and developments
7.10.6. Strategy share (%)
LIST OF TABLES
TABLE 1. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY TYPE OF DELIVERY SYSTEM, 2016-2023 ($MILLION)
TABLE 2. GLOBAL PASSIVE DELIVERY SYSTEM MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 3. PASSIVE DELIVERY SYSTEM MARKET, BY REGION 2016-2023 ($MILLION)
TABLE 4. NORTH AMERICA PASSIVE DELIVERY SYSTEM MARKET, BY COUNTRY 2016-2023 ($MILLION)
TABLE 5. EUROPE PASSIVE DELIVERY SYSTEM MARKET, BY COUNTRY 2016-2023 ($MILLION)
TABLE 6. ASIA-PACIFIC PASSIVE DELIVERY SYSTEM MARKET, BY COUNTRY 2016-2023 ($MILLION)
TABLE 7. LAMEA PASSIVE DELIVERY SYSTEM MARKET, BY COUNTRY 2016-2023 ($MILLION)
TABLE 8. GLOBAL ACTIVE DELIVERY SYSTEM MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 9. ACTIVE DELIVERY SYSTEM MARKET, BY REGION 2016-2023 ($MILLION)
TABLE 10. NORTH AMERICA ACTIVE DELIVERY SYSTEM MARKET, BY COUNTRY 2016-2023 ($MILLION)
TABLE 11. EUROPE ACTIVE DELIVERY SYSTEM MARKET, BY COUNTRY 2016-2023 ($MILLION)
TABLE 12. ASIA-PACIFIC ACTIVE DELIVERY SYSTEM MARKET, BY COUNTRY 2016-2023 ($MILLION)
TABLE 13. LAMEA ACTIVE DELIVERY SYSTEM MARKET, BY COUNTRY 2016-2023 ($MILLION)
TABLE 14. GLOBAL ELECTRICALLY-BASED DRUG DELIVERY SYSTEM MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 15. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 16. TRANSDERMAL DRUG DELIVERY SYSTEM MARKET FOR ANALGESICS, BY REGION, 2016-2023 ($MILLION)
TABLE 17. TRANSDERMAL DRUG DELIVERY SYSTEM MARKET FOR HORMONE REPLACEMENT THERAPY, BY REGION, 2016-2023 ($MILLION)
TABLE 18. TRANSDERMAL DRUG DELIVERY SYSTEM MARKET FOR ISCHEMIC STROKE, BY REGION, 2016-2023 ($MILLION)
TABLE 19. TRANSDERMAL DRUG DELIVERY SYSTEM MARKET FOR MOTION SICKNESS, BY REGION, 2016-2023 ($MILLION)
TABLE 20. TRANSDERMAL DRUG DELIVERY SYSTEM MARKET FOR SMOKING CESSATION, BY REGION, 2016-2023 ($MILLION)
TABLE 21. TRANSDERMAL DRUG DELIVERY SYSTEM MARKET FOR OTHERS, BY REGION, 2016-2023 ($MILLION)
TABLE 22. TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 23. NORTH AMERICA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY COUNTRY 2016-2023 ($MILLION)
TABLE 24. NORTH AMERICA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 25. NORTH AMERICA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 27. EUROPE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY COUNTRY 2016-2023 ($MILLION)
TABLE 28. EUROPE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 29. EUROPE TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY DISEASE PATHOLOGY, 2016-2023 ($MILLION)
TABLE 30. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY COUNTRY 2016-2023 ($MILLION)
TABLE 31. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 32. ASIA-PACIFIC TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY DISEASE PATHOLOGY, 2016-2023 ($MILLION)
TABLE 33. LAMEA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY COUNTRY 2016-2023 ($MILLION)
TABLE 34. LAMEA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 35. LAMEA TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, BY DISEASE PATHOLOGY, 2016-2023 ($MILLION)
TABLE 36. ACRUX: COMPANY SNAPSHOT
TABLE 37. ACRUX: OPERATING SEGMENTS
TABLE 38. BAYER: COMPANY SNAPSHOT
TABLE 39. BAYER: OPERATING SEGMENTS
TABLE 40. BOEHRINGER: COMPANY SNAPSHOT
TABLE 41. BOEHRINGER: OPERATING SEGMENTS
TABLE 42. BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
TABLE 43. BRISTOL-MYERS SQUIBB: OPERATING SEGMENTS
TABLE 44. ECHO: COMPANY SNAPSHOT
TABLE 45. ECHO: OPERATING SEGMENTS
TABLE 46. ENDO: COMPANY SNAPSHOT
TABLE 47. ENDO: OPERATING SEGMENTS
TABLE 48. GSK: COMPANY SNAPSHOT
TABLE 49. GSK: OPERATING SEGMENTS
TABLE 50. J&J: COMPANY SNAPSHOT
TABLE 51. J&J: OPERATING SEGMENTS
TABLE 52. MYLAN: COMPANY SNAPSHOT
TABLE 53. MYLAN: OPERATING SEGMENTS
TABLE 54. NOVARTIS: COMPANY SNAPSHOT
TABLE 55. NOVARTIS: OPERATING SEGMENTS
LIST OF FIGURES
FIGURE 1. GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET, 2016-2023
FIGURE 2. SEGMENTATION OF GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET
FIGURE 3. TOP INVESTMENT POCKETS IN GLOBAL TRANSDERMAL DRUG DELIVERY SYSTEM MARKET
FIGURE 4. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (2016)
FIGURE 5. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION, (2014-2016)
FIGURE 6. TOP WINNING STRATEGIES: NATURE AND TYPE
FIGURE 7. TOP COMPANIES AND THEIR STRATEGIES
FIGURE 8. DETAILED STRUCTURE OF COMPANIES AND NATURE OF STRATEGIES
FIGURE 9. DETAILED STRUCTURE OF COMPANIES AND TYPE OF STRATEGIES
FIGURE 10. MARKET SHARE ANALYSIS, 2016
FIGURE 11. IMPACT ANALYSIS, TRANSDERMAL DRUG DELIVERY SYSTEM MARKET
FIGURE 12. GLOBAL MATRIX DELIVERY SYSTEM MARKET, 2016-2023 ($MILLION)
FIGURE 13. GLOBAL RESERVOIR DELIVERY SYSTEM MARKET, BY TYPE, 2016-2023 ($MILLION)
FIGURE 14. GLOBAL STRUCTURE-BASED DRUG DELIVERY SYSTEM MARKET, 2016-2023 ($MILLION)
FIGURE 15. GLOBAL IONTOPHORESIS DRUG DELIVERY SYSTEM MARKET, 2016-2023 ($MILLION)
FIGURE 16. GLOBAL ELECTROPORATION DRUG DELIVERY SYSTEM MARKET, 2016-2023 ($MILLION)
FIGURE 17. GLOBAL SONOPHORESIS DRUG DELIVERY SYSTEM MARKET, 2016-2023 ($MILLION)
FIGURE 18. GLOBAL OTHER DRUG DELIVERY SYSTEM MARKET, 2016-2023 ($MILLION)
FIGURE 19. ACRUX: FINANCIALS
FIGURE 20. BAYER: FINANCIALS
FIGURE 21. BOEHRINGER: FINANCIALS
FIGURE 22. BRISTOL-MYERS SQUIBB: FINANCIALS
FIGURE 23. ECHO: FINANCIALS
FIGURE 24. ENDO: FINANCIALS
FIGURE 25. GSK: FINANCIALS
FIGURE 26. J&J: FINANCIALS
FIGURE 27. MYLAN: FINANCIALS
FIGURE 28. NOVARTIS: FINANCIALS
Contact us at the Consulting WP office nearest to you or submit a business inquiry online.
Subscribe to Our Newsletter
Published On : December 2019
$ 3600
Published On : December 2019
$ 3600
Published On : December 2019
$ 3600
Published On : December 2019
$ 3600
Published On : December 2019
$ 3600
Published On : December 2019
$ 3600
